MEDAMI 2014 - III MEDITERRANEAN THEMATIC WORKSHOP IN ADVANCED MOLECULAR IMAGING

Session

Combined prostate/OB/GYN and endoscopic session

4 Sept 2014, 15:30

Hotel Portoconte

Conveners

Combined prostate/OB/GYN and endoscopic session

• Stan Majewski (West Virginia University)
• Markus Schwaiger

Combined prostate/OB/GYN and endoscopic session

• Stan Majewski (West Virginia University)
• Markus Schwaiger

87. Gastrointestinal endoscopy I

Ivo Boskowski (Catholic University of Rome, Digestive Endoscopy Unit)

04/09/2014, 15:30

In the past three decades gastrointestinal endoscopy has dramatically evolved. This evolution passed from rigid endoscopes trough fiber optic endoscopes to high definition video endoscopes that are used today. Physics and medicine has always been in symbiosis, especially in the field of development of devices and accessories. Gastrointestinal endoscopy endoscopy today is either diagnostic and...

88. Role of EndoTOF PET_US in pancreatic pathology

R. Laugier (University of Nice)

04/09/2014, 15:55

Pancreas is a deep organ in the abdominal cavity and endoscopy has followed immense improvements thanks to technology advances. Pancreatic cancer frightens everyone in view of its growing incidence and hopeless prognosis still in 2014. It is not conceivable to imagine a program of pancreatic cancer screening in the general population due to the lack of early symptoms. By contrast, some...

89. Present status of prostate cancer treatment and the role of imaging

César David Vera Donoso (La Fe Universitary Hospital)

04/09/2014, 16:20

90. Present status of OB/GYN cancer treatment and the role of imaging

Alessia Di Legge (University Cattolica Rome)

04/09/2014, 16:45

Improvement in treatment for gynecological carcinoma makes it possible to offer optimal and personalized treatment. Pretreatment staging is crucial to plan the best treatment strategy. Gynecological cancer staging is based on clinical examination and histological findings. However, many diagnostic methods are entered into clinical practice. Between the more sophisticated imaging techniques,...

91. Prospects for imaging prostate cancer with PET/CT and PET/MR

Maurizio Conti (Siemens)

04/09/2014, 17:40

Prostate cancer is one of the most common forms of cancer among men. Early diagnosis, correct staging, accurate detection of metastasis, and monitoring of the therapy are the key tasks that could greatly benefit from medical imaging. After a review of the main developments in the field of PET tracers for prostate cancer, the impact of improved PET instrumentation with good spatial resolution...

92. 18F-Choline: Is shine-effect an issue for prostate SUV quantification? An evaluation based on Monte Carlo simulations of the XCAT phantom

Jesus Silva-Rodriguez (Health Research Institute)

04/09/2014, 18:05

18-fluorine-choline (18F-Choline) is a relatively new radiopharmaceutical for Positron Emission Tomography (PET), proposed as an alternative for 11-carbon-choline (11C-Choline), and indicated for staging, restaging and therapy monitoring in prostate cancer. In clinical routine, 18F-Choline images are eventually evaluated using a quantitative parameter known as Standardized Uptake Value (SUV)....

94. TRUS_Tof_PET Project

Dr Stan Majewski

04/09/2014, 18:30

The most certain diagnosis of prostate cancer is based on histopathology analysis of biopsy samples. Biopsy decision is based on highly non-specific elevated PSA (Prostate Specific Antigen) factor in blood. Currently biopsy is realized with use of TRUS. Samples are taken by ~2mm biopsy needle. TRUS is not sensitive for small cancer lesions, therefore it is generally used for biopsy needle...